Supernus (SUPN) Rule 144 Filing for 25,000 Shares valued $1.2M
Rhea-AI Filing Summary
Notice of proposed sale under Rule 144 for Supernus Pharmaceuticals, Inc. (SUPN) reports an intended sale of 25,000 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of
Positive
- Brokered sale through Morgan Stanley indicates orderly execution channel for the 25,000 shares
- Acquisition documented (in-kind distribution from NEA Partners on
05/01/2012 ), supporting ownership provenance
Negative
- Insider selling activity: recent Rule 10b5-1 sales of 3,588, 1,412, and 1,000 shares occurred in
08/2025 , totaling 6,000 shares - Represents potential dilution signal: 25,000 shares equal a measurable sale against 56,073,088 outstanding shares
Insights
Planned sale is formally disclosed and appears executed via broker and 10b5-1 plans.
The filing documents a proposed Rule 144 sale of 25,000 common shares valued at
Dependencies and compliance risks include adherence to Rule 144 timing/volume limits and the representational statement about no undisclosed material information. Recent 10b5-1 sales by the same account—totaling 6,000 shares in